UNSPSC 51292605: Aptazapine maleate

This classification denotes the maleate form of an antidepressant agent with the molecular structure C16H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 240J927J1R chemically known as (+/-)-1,3,4,14b-tetrahydro-2-methyl-2h,10h-pyrazino(1,2-a)pyrrolo(2,1-c)(1,4)benzodiazepine, but more commonly known as aptazapine, which bears US NIH Compound Identifier 51355. European Medicines Agency schedules Aptazapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05547MIG.

UNSPSC 51292605 Aptazapine maleate is a Commodity code representing a specific active pharmaceutical ingredient, though recent state and local opportunities tagged to it diverge significantly from this narrow scope. Procurement activity under this code encompasses broader pharmaceutical purchasing — generic multi-source drugs and over-the-counter products supplied through authorized wholesalers, naloxone and drug deactivation systems for public health initiatives, and direct-to-manufacturer prescription fulfillment programs designed to improve cost management and supply-chain efficiency. The issuing bodies include state health and human services agencies, county public health departments, and multistate cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions. Work is characterized by competitive bidding for standardized products with fixed pricing models, compliance with federal manufacturing and supply-chain security standards (cGMP, DSCSA, FDA requirements), and administrative overhead fees.

Recent activity spans Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the contract includes a three-month probationary period and potential FEMA funding with associated federal compliance obligations. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be awarded by May 15, 2026 with effectiveness July 1, 2026, requiring vendors to maintain relationships with at least two of three authorized wholesalers and comply with a 3 percent administrative fee structure. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling intent to develop formal procurement specifications in a subsequent RFP phase.